Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Panupong Hansrivijit, Wisit Cheungpasitporn, Charat Thongprayoon, Nasrollah Ghahramani
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2020-04-01
Edice:BMC Nephrology
Témata:
Rituximab
FSGS
Focal segmental glomerulosclerosis
MCD
Minimal change disease
Nephrotic syndrome
On-line přístup:http://link.springer.com/article/10.1186/s12882-020-01797-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky